Patent: 10,143,723
✉ Email this page to a colleague
Summary for Patent: 10,143,723
Title: | Methods of using OX40 ligand encoding polynucleotides |
Abstract: | The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof. |
Inventor(s): | Frederick; Joshua P. (Boston, MA), Bai; Ailin (Newton, MA) |
Assignee: | ModernaTX, Inc. (Cambridge, MA) |
Application Number: | 15/996,140 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,143,723 |
Patent Claims: | see list of patent claims |
Details for Patent 10,143,723
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2035-12-23 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-12-23 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-12-23 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2035-12-23 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2035-12-23 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2035-12-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |